Recursion Pharmaceuticals

Drug candidate for familial adenomatous polyposis (FAP) in Phase 1b/2 TUPELO trial

REC-4881 is a drug candidate currently in Phase 1b/2 clinical trials (TUPELO trial) for the treatment of familial adenomatous polyposis (FAP), a rare disease. The company has announced positive Phase 1b/2 results from the ongoing trial.

Biopharma's most powerful supercomputer for AI drug discovery

BioHive-2 is a supercomputer built in partnership with NVIDIA to process Recursion's massive datasets. It provides the computational power necessary to train intelligent machine learning models for AI drug discovery and development, helping rapidly identify new targets and design highly optimized molecules.

Selective MALT1 inhibitor for relapsed or refractory B-cell lymphomas in Phase 1

REC-3565 is a selective MALT1 inhibitor currently in Phase 1 clinical study for the treatment of relapsed or refractory B-cell lymphomas. The company announced first patient dosed in the Phase 1 clinical study.

AI platform to industrialize drug discovery from target identification to clinical trial enrollment

The Recursion Operating System is a proprietary AI drug discovery and development platform that spans target identification to clinical trial enrollment. It is powered by one of the world's largest proprietary biological and chemical datasets (>50 petabytes spanning phenomics, transcriptomics, proteomics, ADME, and de-identified patient data). The platform uses automated wet labs with robotics and computer vision to capture millions of cell experiments per week, feeding all results back into the system in a continuously improving feedback loop.